App-based investigation of patient-reported outcomes in TYSABRI therapy

App-based investigation of patient-reported outcomes in TYSABRI therapy - TRAIT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00024387

Enrollment

600

Registered

2021-02-15

Start date

2021-04-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G35

Interventions

Group 1: Prior, during an after an infusion of natalizumab neuropsychological testing will be done.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: relapsing remitting multiple sclerosis

Exclusion criteria

Exclusion criteria: progressve multiple scleroses and patients without a therapy with natalizumab

Design outcomes

Primary

Measure	Time frame
Quality of life, fatigue and cognition during natalizumab therapy	—

Secondary

Measure	Time frame
Parameter change during 12 months	—

Countries

Germany

Contacts

Public ContactBirguel Senyildiz

Studienzentrum - NeuroPoint

trait@neurosys.de073115979794

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026